E. S. Rogers

A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

J. Keogh, J. Stewart, S. Bird, 2011, BMC Cancer.

A multi‐targeted treatment approach to cancer cachexia: Auckland's Cancer Cachexia evaluating Resistance Training (ACCeRT) trial

B. Arroll, J. Keogh, J. Stewart, 2020 .

Auckland’s Cancer Cachexia evaluating Resistance Training (ACCeRT) main study results

B. Arroll, J. Keogh, J. Stewart, 2019 .

Updated protocol and guest participant results from the ACCeRT clinical study

B. Arroll, J. Keogh, J. Stewart, 2020 .

A randomised feasibility study of EPA and Cox-2 inhibitor ( Celebrex ) , Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachetic patients-ACCeRT study

J. Keogh, J. Stewart, S. Bird, 2016 .

Acceptability, Compliance, and Safety of Non-small Cell Lung Cancer Cachectic Participants Continuing Compassionate Access in the ACCeRT Clinical Study

B. Arroll, J. Stewart, G. Sequeira, 2021, Journal of Health Science and Medical Research.

Body composition skeletal muscle analysis in cancer cachexia studies: Is there a place for 3T MRI analysis?

B. Pontré, W. Ormiston, R. MacLeod, 2018, JCSM Clinical Reports.